Regular aerobic exercise may improve cardiorespiratory fitness while modulating systemic inflammation and oxidative stress. Spinning, as a structured indoor cycling modality, provides a practical aerobic exercise model with adjustable intensity and duration, but its effects on redox balance, inflammatory status, aerobic capacity, and cardiac functional parameters may vary according to individual recovery and nutritional status. Magnesium is an essential micronutrient involved in energy metabolism, muscle contraction-relaxation, ion regulation, and inflammatory and oxidative pathways; therefore, magnesium use may be relevant to exercise adaptation and recovery. This study aims to evaluate the associations of magnesium use and spinning training with oxidative stress, inflammation, aerobic capacity, and cardiac parameters. In this context, biochemical markers related to oxidative/antioxidant status and inflammation, aerobic performance indicators, and echocardiographic cardiac function parameters will be assessed together. The study is expected to provide real-world evidence on whether magnesium use in individuals participating in spinning training is associated with more favorable redox, inflammatory, aerobic, and cardiac profiles.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
48
Participants will participate in a structured spinning training program during the study period. The program will consist of supervised indoor cycling sessions performed at a planned frequency, duration, and intensity.
Participants will receive oral magnesium supplementation during the study period in addition to the structured spinning training program.
Karamanoğlu Mehmetbey University, Faculty of Sport Sciences
Karaman, Turkey (Türkiye)
Change in Maximal Oxygen Uptake (VO₂max)
Maximal oxygen uptake (VO₂max, mL/kg/min) will be assessed using a graded exercise test. The change in VO₂max from baseline to 6 weeks will be evaluated.
Time frame: Baseline and 6 weeks
Change in Serum Magnesium Concentration
Serum magnesium concentration (mg/dL) will be measured using standard laboratory methods. The change in serum magnesium levels from baseline to 6 weeks will be evaluated.
Time frame: Baseline and 6 weeks
Change in Total Antioxidant Status (TAS)
Serum total antioxidant status (TAS, mmol Trolox equivalent/L) will be measured using commercially available assay kits. The change in TAS from baseline to 6 weeks will be evaluated.
Time frame: Baseline and 6 weeks
Change in Total Oxidant Status (TOS)
Serum total oxidant status (TOS, μmol H₂O₂ equivalent/L) will be measured using commercially available assay kits. The change in TOS from baseline to 6 weeks will be evaluated.
Time frame: Baseline and 6 weeks
Change in Paraoxonase-1 Activity (PON1)
Serum paraoxonase-1 (PON1, U/L) activity will be determined using spectrophotometric methods. The change in PON1 activity from baseline to 6 weeks will be evaluated.
Time frame: Baseline and 6 weeks
Change in Arylesterase Activity (ARE)
Serum arylesterase (ARE, kU/L) activity will be determined using spectrophotometric methods. The change in ARE activity from baseline to 6 weeks will be evaluated.
Time frame: Baseline and 6 weeks
Change in High-Sensitivity C-Reactive Protein (hs-CRP)
Serum high-sensitivity C-reactive protein (hs-CRP, mg/L) concentration will be measured using standard laboratory methods. The change in hs-CRP levels from baseline to 6 weeks will be evaluated.
Time frame: Baseline and 6 weeks
Change in Interleukin-6 (IL-6)
Serum interleukin-6 (IL-6, pg/mL) concentration will be measured using enzyme-linked immunosorbent assay methods. The change in IL-6 levels from baseline to 6 weeks will be evaluated.
Time frame: Baseline and 6 weeks
Change in Tumor Necrosis Factor-Alpha (TNF-α)
Serum tumor necrosis factor-alpha (TNF-α, pg/mL) concentration will be measured using enzyme-linked immunosorbent assay methods. The change in TNF-α levels from baseline to 6 weeks will be evaluated.
Time frame: Baseline and 6 weeks
Change in Serum Potassium Concentration
Serum potassium concentration (mmol/L) will be measured using standard biochemical methods. The change in serum potassium levels from baseline to 6 weeks will be evaluated.
Time frame: Baseline and 6 weeks
Change in Serum Calcium Concentration
Serum calcium concentration (mg/dL) will be measured using standard biochemical methods. The change in serum calcium levels from baseline to 6 weeks will be evaluated.
Time frame: Baseline and 6 weeks
Change in N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)
Serum N-terminal pro-B-type natriuretic peptide (NT-proBNP, pg/mL) concentration will be measured using immunoassay methods. The change in NT-proBNP levels from baseline to 6 weeks will be evaluated.
Time frame: Baseline and 6 weeks
Change in Left Ventricular Ejection Fraction (LVEF)
Left ventricular ejection fraction (LVEF, %) will be assessed by transthoracic echocardiography. The change in LVEF from baseline to 6 weeks will be evaluated.
Time frame: Baseline and 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.